Ultra-low fouling and functionalizable zwitterionic coatings grafted onto SiO2 via a biomimetic adhesive group for sensing and detection in complex media

Department of Chemical Engineering, University of Washington, Seattle, WA 98195-1750, USA.
Biosensors & Bioelectronics (Impact Factor: 6.45). 03/2010; 25(10):2276-82. DOI: 10.1016/j.bios.2010.03.012
Source: PubMed

ABSTRACT Non-specific protein binding from human plasma and serum has severely hindered the full capabilities of biosensors concerned with cancer biomarker detection. Currently, there is a strong desire for developing new materials which allow for the convenient attachment of an ultra-low fouling and functionalizable surface coating which can be used for highly sensitive and label-free detection of target analytes directly from complex media. In this work, a short 20 min in situ "graft to" protocol using Tris pH 8.5 buffer was developed for zwitterionic carboxybetaine methacrylate (CBMA) polymer conjugates containing the adhesive biomimetic moiety, 3,4-dihydroxy-L-phenylalanine (DOPA), on SiO(2) substrates. Using a surface plasmon resonance (SPR) biosensor, different buffers, pH values, salt concentrations, and temperatures were investigated for determining the "graft to" conditions that yield dense polymer films which both minimize non-specific protein adsorption and maximize antibody immobilization. The optimized surface coatings were shown to be highly protein resistant to 100% human blood plasma and serum. Subsequent antibody functionalized surfaces without any blocking agents enabled the specific detection of the cancer biomarker ALCAM directly from undiluted human serum down to 64 ng/mL. The successful use of this zwitterionic surface coating for detection from complex media on SiO(2) surfaces indicates its potential for broad impacts in the development of implantable medical devices, in vivo diagnostics, and nano-scale biosensors.

1 Follower
  • Source
    • "One example is to use 3,4-dihy- droxy-L-phenylalanine (DOPA) as the surface anchor group to graft zwitterionic pCB Figure 3. Three approaches to immobilize pCBs onto materials surfaces. to the surface for cancer biomarker detection.[19] Another convenient 'graft-to' strategy was to use hydrophobic–hydrophobic interactions to immobilize polymers onto the substrate, using a triblock copolymer containing a poly(propylene oxide) hydrophobic block and two hydrophilic CB blocks.[59] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Zwitterionic polycarboxybetaine (pCB)-based materials have drawn special attention due to their outstanding properties of resisting proteins adsorption, biofilm formation and cell attachment on a variety of substrates and surfaces, reducing the uptake of pCB-coated nanosized materials, as well as providing the capability of further functionalization. Zwitterionic pCBs have been proven to be excellent choices for many applications, not only limited to the field of antifouling. This review will summarize the recent progress on the development of pCB materials and the understanding of the structure-function-property relationships of carboxybetaine materials.
    Journal of Biomaterials Science Polymer Edition 06/2014; 25(14-15):1-12. DOI:10.1080/09205063.2014.927300 · 1.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We show that optimizing EUV yield from laser-heated droplet targets requires matching the pulsewidth to the droplet size if the emission feature is from collisional excitation; it can be longer if the feature is from recombination.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer is one of the most common and leading causes of cancer death in women. Early diagnosis, selection of appropriate therapeutic strategies, and efficient follow-up play an important role in reducing mortality. Recently, HER-2/neu in breast cancer has been routinely used to guide treatment of using Trastuzumab in less than 25-30% of patients. More new biomarkers will be still expected in the future to tailor treatments. However, there are still many obstacles in developing clinically useful biomarker tests for clinical practice. A lack of specificity of tumor markers and lack of sensitivity of testing systems have been noticed, which limit their clinical use. Finding biomarkers for breast cancer could allow physicians to identify individuals who are susceptible to certain types and stages of cancer to tailor preventive and therapeutic modalities based on the genotype and phenotype information. These biomarkers should be cancer specific, and sensitively detectable in a wide range of specimen(s) containing cancer-derived materials, including body fluids (plasma, serum, urine, saliva, etc.), tissues, and cell lines. This review highlights the new trends and approaches in breast cancer biomarker discovery, which could be potentially used for early diagnosis, development of new therapeutic approaches, and follow-up of patients.
    Genetic Testing and Molecular Biomarkers 10/2009; 13(5):565-71. DOI:10.1089/gtmb.2009.0060 · 1.15 Impact Factor
Show more